Cereno Scientific AB (publ) (STO:CRNO.B)
4.362
+0.124 (2.93%)
At close: Sep 4, 2026
Cereno Scientific AB Revenue
Cereno Scientific AB had revenue of 52.56M SEK in the quarter ending June 30, 2026, with 750.41% growth. This brings the company's revenue in the last twelve months to 113.72M, up 65.48% year-over-year. In the year 2025, Cereno Scientific AB had annual revenue of 44.27M, down -45.28%.
Revenue (ttm)
113.72M
Revenue Growth
+65.48%
P/S Ratio
-4,507.64
Revenue / Employee
-29.34K
Employees
10
Market Cap
1.32B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.27M | -36.63M | -45.28% |
| Dec 31, 2024 | 80.90M | 31.63M | 64.18% |
| Dec 31, 2023 | 49.28M | -8.26M | -14.36% |
| Dec 31, 2022 | 57.54M | 12.73M | 28.42% |
| Dec 31, 2021 | 44.81M | 36.58M | 444.85% |
| Dec 31, 2020 | 8.22M | 1.29M | 18.64% |
| Dec 31, 2018 | 6.93M | -2.47M | -26.28% |
| Dec 31, 2017 | 9.40M | 4.73M | 101.42% |
| Dec 31, 2016 | 4.67M | 4.09M | 713.19% |
| Dec 31, 2015 | 574.01K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.58B |
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Newbury Pharmaceuticals AB | 35.02M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
Cereno Scientific AB News
- 9 days ago - Cereno Scientific AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Cereno Scientific AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Cereno Scientific AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Cereno Scientific AB Annual report: Q4 2025 - Filings
- 7 months ago - Cereno Scientific AB Transcript: CMD 2026 - Transcripts
- 9 months ago - Cereno Scientific AB Quarterly report: Q3 2025 - Filings
- 12 months ago - Cereno Scientific AB Transcript: GoCo Investor Days - Transcripts